Company intelligence / Profile preview

MC Diagnostics

Wirral, England, United Kingdom
Ownership
Private
Development stage
Other
01

Overview

MC Diagnostics has commercialized the ALDAS platform for multiplexed molecular diagnostics including HLA typing and blood group determination; in partnership with ACT Genomics, they have achieved notable advances in fusion genechip oncology diagnostics such as the ACTSpot NTRK, with rapid point-of-care results closely matching NGS performance[1][2][4].

Therapeutic areas
HematologyImmunologyOncology
Modalities
DeviceDiagnostic assay
Industry
Molecular Diagnostics
02

Partnerships

ACT Genomics

Beyond the preview

Go deeper on MC Diagnostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Full profile access

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Full profile access

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Full profile access

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Full profile access

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Full profile access

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on MC Diagnostics.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call